II. Mechanism
III. Causes
- Infections
- Acute Graft Versus Host Disease
- Allogeneic Graft with Hematopoietic Stem Cell Transplant
- Original use of term "Cytokine Storm"
- Allogeneic Graft with Hematopoietic Stem Cell Transplant
-
Chemotherapy
- Muromonab-CD3 (OKT3) Infusion
- Original use of term "Cytokine Release Syndrome"
-
Chimeric Antigen Receptor T Cell Therapy (CAR T-Cell Therapy)
- Onset within the first week of Engineered CAR T Cell infusion, and peaks within the first 2 weeks
- CAR T Cells stimulate release of inflammatory Cytokines (e.g. Interleukin 6, Interferon gamma)
- Severity of reaction is higher with greater tumor burden
- Muromonab-CD3 (OKT3) Infusion
IV. Findings: Symptoms and Signs
- Prodrome: Mild Flu-Like Symptoms
- Fatigue
- Malaise
- Low grade fever
- Headache
- Myalgia
- Arthralgia
- Rash
- Later: Vascular Leak and Multi-organ system failure
- High Fever
- Cardiovascular
- Hypotension and shock
- Tachycardia
- Cardiomyopathy with decreased ejection fraction
- Respiratory
- Neurologic
- Altered Level of Consciousness or Confusion
- Word-finding difficulty
- Headaches
- Hallucinations
- Focal Deficits (Aphasia, Hemiparesis, Cranial Nerve palsies)
- Seizures
- Somnolence
V. Labs
- Pancytopenia
-
Acute Kidney Injury
- Increased Serum Creatinine
- Increased hepatic enzymes
- Abnormal Coagulation Factors
- C-Reactive Protein (CRP)
VI. Differential Diagnosis
- Sepsis
- Tumor Lysis Syndrome
- Anaphylaxis or other severe Adverse Drug Reaction
-
Hemophagocytic Lymphohistiocytosis (HLH)
- High fever
- Increased Serum Ferritin
- Increased Serum Triglycerides
-
Macrophage activation syndrome (MAS)
- Patients with CRS-associated HLH display the typical clinical and laboratory findings of HLH/MAS such as high fevers,
VII. Management
- Stabilization and Supportive Care (often Critical Care)
- Cover with culture and broad spectrum Antibiotics to cover Neutropenic Fever until infection is excluded
- Antipyretics
- Intravenous Fluids
- Vasopressors as needed
- Mechanical Ventilation as needed
-
Tocilizumab (IL-6 receptor Antagonist)
- Dosing: 8 mg/kg (up to 800 mg) or for <30 kg, use 12 mg/kg
- Siltuimab is being studied as alternative agent in 2020
- Blockade of of IL-6 decreases production of proinflammatory Cytokines and acute phase reactants
- FDA Approved for several Rheumatologic Conditions and CRS due to CAR T-Cell Therapy
- Experimental use in CRS due to COVID-19
- Adverse effects: Reactivated VZV and Tb, Neutropenia, Thrombocytopenia, increased LFTs, Lipids, GI perforation
-
Corticosteroids
- Indicated in Tocilizumab-resistant CRS or CRES
- Dexamethasone 10-20 mg IV every 6 hours
- Corticosteroids decrease CAR T Cell efficacy (avoid in mild to moderate cases)
VIII. Complications
- Disseminated Intravascular Coagulation
- Acute Respiratory Distress Syndrome (ARDS)
- Multi-System Organ Failure
IX. References
- Kamer and LoVecchio (2020) Crit Dec Emerg Med 34(8): 24
- Jansson and Pallin (2020) Crit Dec Emerg Med 34(4): 19-28
- Fajgenbaum (2020) N Engl J Med 383:2255-73 [PubMed]
- Shimabukuro-Vornhagen (2018) J Immunother Cancer 6: 56 +PMID:29907163 [PubMed]